Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000081884 | SCV000113819 | uncertain significance | not provided | 2012-11-02 | criteria provided, single submitter | clinical testing | |
Counsyl | RCV000671667 | SCV000796662 | likely benign | Cohen syndrome | 2017-12-28 | criteria provided, single submitter | clinical testing | |
Invitae | RCV000671667 | SCV001096843 | likely benign | Cohen syndrome | 2024-01-12 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002415579 | SCV002726076 | likely benign | Inborn genetic diseases | 2017-09-26 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Prevention |
RCV003915093 | SCV004734869 | likely benign | VPS13B-related disorder | 2021-08-11 | criteria provided, single submitter | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |
Natera, |
RCV000671667 | SCV001456249 | uncertain significance | Cohen syndrome | 2020-01-24 | no assertion criteria provided | clinical testing |